Perspective raises $175M, extends cash runway to late 2027, advances three clinical programs

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read

Key Changes

• high

  Completed $175M underwritten offering in February 2026 at $3.79/share, extending cash runway from late 2026 to late 2027 and providing capital for clinical trials and manufacturing expansion.

  MD&A: Capital Raise & Cash Runway verify on EDGAR →
• high

  VMT-α-NET safety committee approved dose escalation to Cohort 3, but enrollment awaits FDA alignment; 40 patients now dosed in Cohort 2, up from 30 in prior quarter.

  MD&A: VMT-α-NET Trial Progress verify on EDGAR →
• high

  Dosed first patient in PSV359 trial (FAP-α target) in April 2025 after FDA approval, expanding pipeline to three clinical-stage assets beyond VMT-α-NET and VMT01.

  MD&A: PSV359 IND Approval verify on EDGAR →